Spots Global Cancer Trial Database for kinase
Every month we try and update this database with for kinase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | NCT01140568 | Glioma | nilotinib | 18 Years - | University of California, San Diego | |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | NCT04106219 | Neuroblastoma | LY3295668 Erbum... Topotecan Cyclophosphamid... | 2 Years - 21 Years | Eli Lilly and Company | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) | NCT01468467 | Leukemia, Myelo... | AC220 | 18 Years - | Daiichi Sankyo | |
| A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01390337 | Leukemia, Myelo... | AC220 daunorubicin cytarabine | 18 Years - 60 Years | Daiichi Sankyo | |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | NCT01449370 | Metastatic Soli... | TAK-117 | 18 Years - | Takeda | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
